Cargando…
New challenges in the use of nanomedicine in cancer therapy
Nanomedicines are applied as alternative treatments for anticancer agents. For the treatment of cancer, due to the small size in nanometers (nm), specific site targeting can be achieved with the use of nanomedicines, increasing their bioavailability and conferring fewer toxic side effects. Additiona...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805951/ https://www.ncbi.nlm.nih.gov/pubmed/34856849 http://dx.doi.org/10.1080/21655979.2021.2012907 |
_version_ | 1784643336764653568 |
---|---|
author | Rasool, Mahmood Malik, Arif Waquar, Sulayman Arooj, Mahwish Zahid, Sara Asif, Muhammad Shaheen, Sumaira Hussain, Abrar Ullah, Hamid Gan, Siew Hua |
author_facet | Rasool, Mahmood Malik, Arif Waquar, Sulayman Arooj, Mahwish Zahid, Sara Asif, Muhammad Shaheen, Sumaira Hussain, Abrar Ullah, Hamid Gan, Siew Hua |
author_sort | Rasool, Mahmood |
collection | PubMed |
description | Nanomedicines are applied as alternative treatments for anticancer agents. For the treatment of cancer, due to the small size in nanometers (nm), specific site targeting can be achieved with the use of nanomedicines, increasing their bioavailability and conferring fewer toxic side effects. Additionally, the use of minute amounts of drugs can lead to cost savings. In addition, nanotechnology is effectively applied in the preparation of such drugs as they are in nm sizes, considered one of the earliest cutoff values for the production of products utilized in nanotechnology. Early concepts described gold nanoshells as one of the successful therapies for cancer and associated diseases where the benefits of nanomedicine include effective active or passive targeting. Common medicines are degraded at a higher rate, whereas the degradation of macromolecules is time-consuming. All of the discussed properties are responsible for executing the physiological behaviors occurring at the following scale, depending on the geometry. Finally, large nanomaterials based on organic, lipid, inorganic, protein, and synthetic polymers have also been utilized to develop novel cancer cures. |
format | Online Article Text |
id | pubmed-8805951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-88059512022-02-02 New challenges in the use of nanomedicine in cancer therapy Rasool, Mahmood Malik, Arif Waquar, Sulayman Arooj, Mahwish Zahid, Sara Asif, Muhammad Shaheen, Sumaira Hussain, Abrar Ullah, Hamid Gan, Siew Hua Bioengineered Review Nanomedicines are applied as alternative treatments for anticancer agents. For the treatment of cancer, due to the small size in nanometers (nm), specific site targeting can be achieved with the use of nanomedicines, increasing their bioavailability and conferring fewer toxic side effects. Additionally, the use of minute amounts of drugs can lead to cost savings. In addition, nanotechnology is effectively applied in the preparation of such drugs as they are in nm sizes, considered one of the earliest cutoff values for the production of products utilized in nanotechnology. Early concepts described gold nanoshells as one of the successful therapies for cancer and associated diseases where the benefits of nanomedicine include effective active or passive targeting. Common medicines are degraded at a higher rate, whereas the degradation of macromolecules is time-consuming. All of the discussed properties are responsible for executing the physiological behaviors occurring at the following scale, depending on the geometry. Finally, large nanomaterials based on organic, lipid, inorganic, protein, and synthetic polymers have also been utilized to develop novel cancer cures. Taylor & Francis 2022-01-04 /pmc/articles/PMC8805951/ /pubmed/34856849 http://dx.doi.org/10.1080/21655979.2021.2012907 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Rasool, Mahmood Malik, Arif Waquar, Sulayman Arooj, Mahwish Zahid, Sara Asif, Muhammad Shaheen, Sumaira Hussain, Abrar Ullah, Hamid Gan, Siew Hua New challenges in the use of nanomedicine in cancer therapy |
title | New challenges in the use of nanomedicine in cancer therapy |
title_full | New challenges in the use of nanomedicine in cancer therapy |
title_fullStr | New challenges in the use of nanomedicine in cancer therapy |
title_full_unstemmed | New challenges in the use of nanomedicine in cancer therapy |
title_short | New challenges in the use of nanomedicine in cancer therapy |
title_sort | new challenges in the use of nanomedicine in cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805951/ https://www.ncbi.nlm.nih.gov/pubmed/34856849 http://dx.doi.org/10.1080/21655979.2021.2012907 |
work_keys_str_mv | AT rasoolmahmood newchallengesintheuseofnanomedicineincancertherapy AT malikarif newchallengesintheuseofnanomedicineincancertherapy AT waquarsulayman newchallengesintheuseofnanomedicineincancertherapy AT aroojmahwish newchallengesintheuseofnanomedicineincancertherapy AT zahidsara newchallengesintheuseofnanomedicineincancertherapy AT asifmuhammad newchallengesintheuseofnanomedicineincancertherapy AT shaheensumaira newchallengesintheuseofnanomedicineincancertherapy AT hussainabrar newchallengesintheuseofnanomedicineincancertherapy AT ullahhamid newchallengesintheuseofnanomedicineincancertherapy AT gansiewhua newchallengesintheuseofnanomedicineincancertherapy |